Jason Silverston, MD
Endocrinology, Diabetes & Metabolism · Atlanta, GANPI 1245498609
Payments from drug & device makers
Across 441 payments — averaging $20.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- Novo Nordisk$1K
- Sanofi-aventis U.S. LLC$813
- Corcept Therapeutics$596
- Tandem Diabetes Care, Inc.$574
- Radius Health, Inc.$422
- plus $4K from 33 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 70 | $1,120 |
| Novo Nordisk | 61 | $1,119 |
| Sanofi-aventis U.S. LLC | 37 | $813 |
| Corcept Therapeutics | 21 | $596 |
| Tandem Diabetes Care, Inc. | 21 | $574 |
| Radius Health, Inc. | 13 | $422 |
| Insulet Corporation | 17 | $409 |
| Boehringer Ingelheim | 19 | $349 |
| Amgen(2 entities) | 18 | $348 |
| BETA Bionics, Inc. | 4 | $337 |
| Xeris Pharmaceuticals, Inc. | 17 | $326 |
| AstraZeneca(2 entities) | 21 | $304 |
| Mannkind Corporation | 13 | $254 |
| Abbott | 11 | $238 |
| Bayer | 12 | $236 |
| Dexcom, Inc. | 12 | $220 |
| Amneal Pharmaceuticals LLC | 10 | $154 |
| Cequr Corporation | 3 | $124 |
| AbbVie | 8 | $110 |
| Sequel Med Tech, LLC | 5 | $103 |
| Ascensia Diabetes Care US Inc. | 5 | $94 |
| Antares Pharma, Inc. | 6 | $93 |
| Johnson & Johnson(2 entities) | 6 | $86 |
| Merck | 6 | $86 |
| Medtronic(2 entities) | 4 | $81 |
| Madrigal Pharmaceuticals | 2 | $69 |
| Neurocrine Biosciences, Inc. | 2 | $56 |
| Companion Medical, Inc. | 1 | $54 |
| Ascendis Pharma Endocrinology Inc | 3 | $47 |
| IBSA Pharma Inc. | 3 | $45 |
| Valeritas, Inc. | 2 | $30 |
| Almatica Pharma LLC | 1 | $17 |
| Shire North American Group Inc | 1 | $17 |
| Zealand Pharma US, Inc. | 1 | $17 |
| Exact Sciences | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Acella Pharmaceuticals, LLC | 1 | $15 |
| Vivus LLC | 1 | $12 |
| Recordati_rare_diseases_inc. | 1 | $11 |
How this compares
$9,017 in reported general payments places this provider in the 75th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
See all endocrinology, diabetes & metabolism providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Atlanta
- Bruce BodeAtlanta$18.3M
- Gulliermo UmpierrezAtlanta$6.6M
- David RobertsonAtlanta$1.7M
- Thomas ZieglerAtlanta$1M
- Lawrence PhillipsAtlanta$919K
- Georgia DavisAtlanta$592K
- Jonathan OwnbyAtlanta$565K
- Thaer IdreesAtlanta$505K
- Francisco PasquelAtlanta$376K
- Mary RheeAtlanta$87K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.